

## Eczema Gel

### Ingredient FACTS

**Active Ingredients:** Potassium Sorbate, Sceletium, Colloidal Silver, Avocado Extract, African Griffonia & Passionflower Tinctures, Ozonoids.

**Purpose:** Eczema, Rashes, Irritation, Hives, Insect Bites & Stings

### Use for the management of Eczema, Rashes, Irritation, Hives, Insect Bites & Stings

#### WARNINGS

**For external use only.**

Do not use this medication if you have raw tissue – use the thermo-gel first.

**Ask a doctor or pharmacist before use if you are** using any other topical eczema medications at the same time or immediately following use of this product. This may increase dryness or irritation of the skin. If this occurs, only one medication should be used unless directed by a doctor.

#### When using this product:

- Avoid contact with eyes. If contact occurs, rinse thoroughly with water.

**Uses:** Eczema, Rashes, Irritation, Hives, Insect Bites & Stings



**Eczema:** Clean the affected skin surface with clean water and a non-allergenic soap and dry well. Apply the Eczema Gel to all affected areas. Re-apply every 4-6 hours after re-cleaning the affected surface.

**Insect Bites & Stings:** Clean the affected skin surface with cooled boiled or sterile water. Make sure any residual sting or insect parts are removed from the bite/sting area. Dry and apply a thin layer of the ozonated oil over the bite or sting surface. Seek medical help if necessary. Re-apply every 3-4 hours after re-cleaning the affected surface.

## Active Ingredients:

**Sceletium** is being used successfully by a number of psychiatrists, psychologists and doctors with excellent results for anxiety states and mild to moderate depression; and they can also be used by the lay public as supplements to elevate mood and for stress and tension. In addition to Sceletium's common use for the stress and mental fatigue of modern industrial living, Sceletium has been used as a natural supplement in:

1. Low mood, including grey weather syndrome
2. Anxiety states, including social phobia
3. Irritability in menopause
4. Improvement in libido, when lack of libido is from anxiety or low mood
5. Post-traumatic stress disorder, as part of a support program

## Supporting Research.

**Aiton, W.T.** (1811) Hortus Kewensis or, A Catalogue of the Plants Cultivated in the Royal Botanic Garden at Kew. Vol. III. Longman, Hurst, Rees, Orme, and Brown, London.

**Allison, M.J., Dawson, K.A., Cook, H.M. and Mayberry, W.R.** (1985) Oxalobacter formigenes gen. nov., sp. nov: oxalate-degrading anaerobes that inhabit the gastrointestinal tract. Archives of Microbiology 141, 1-7.

**Argenzio, R.A., Liacos, J.H. and Allison, M.J.** (1988) Intestinal oxalate-degrading bacteria reduce oxalate absorption and toxicity in guinea pigs. Journal of Nutrition 118, 787-792.

**Arridt, R.R. and Kruger, P.E.J.** (1970) Alkaloids from Sceletium joubertii L.Bolus: the Structure of joubertiamine, dihydrojoubertiamine and dehydrojoubertiamine. Tetrahedron Letters 37, 3237-3240.

**Barz, W. and Koster, J.** (1981) Turnover and degradation of secondary (natural) products. In: P.K. Stumpf and E.E. Conn (Eds.), The Biochemistry of Plants: a Comprehensive Treatise. Vol. 7, Academic Press, New York, pp. 35-84.

**Bastida, L, Viladomat, F., Llabres, J. M., Ramires, G., Codina, C. and Rubiralta, M.** (1989) Narcissus alkaloids, VIII mesembrenone: an unexpected alkaloid from Narcissus pallidulus. Journal of Natural Products 52, 478-480.

**Bittrich, V.** (1986) Untersuchungen zu Mermalsbestand, Gliederung und Abgrenzung der Unterfamilie Mesembryanthemoideae (Mchembryanthemaceae Fend) Mitteilungen aus den Institut für Allemeine Botanik (Hamburg) 21, 5-116.

**Bolus, H.M.L.** (1928) Notes of Mesembrianthemum and Some Allied Genera with Descriptions of a Hundred New Species. Part I. Bolus Herbarium, University of Cape Town. The Speciality Press, Cape Town.

**Daniel, S.L., Hartmann, P.A. and Allison, M.J.** (1987) Microbial degradation of oxalate in the gastrointestinal tracts of rats. Applied and Environmental Microbiology 53, 1793-1797.

**Dobkin de Rios, M.** (1990) Hallucinogens: Cross Cultural Perspectives. Prism-Unity, Dorset, U.K.

**Elphick, R.** (1977) Kraal and Castle: Khoikhoi and the Founding of White South Africa. Yale University Press, London.

**Emboden, W.** (1979) Narcotic Plants. MaeMillan, New York.

**Fourie, T.G., Swart, I. and Snyckers, F.O.** (1992) Folk medicine: A viable starting point for pharmaceutical research. South African Journal of Science 88, 190-192.

**Guzinan, G.** (1983) The Genus Psilocybe. Beiliefte Zur Nova Hedwigia 74, 1-439. Kramer, Vaditz.

**Hanson, C.F., Frankos, V.H. and Thompson, W.O.** (1989) Bioavailability of oxalic acid from spinach, sugar beet fibre and a solution of sodium oxalate consumed by female volunteers. *Food Chemistry and Toxicology* 27, 181-184.

**Hartmann, M.E.K.** (1991) *Mesembryanthema*. Contributions from the Bolus Herbarium 13, 75-157.

**Haworth, A. H.** (1794) Observations on the Genus *Mesembryanthemum*, in Two Parts. J. Barker, B. and J. White, London.

**Herre, H.** (1971) *The Genera of the Mesembryanthemaceae*. Tafelberg Publishers, Cape Town.

**Jacobsen, H.** (1960) *A Handbook of Succulent Plants. Vol. III. Mesembryanthemums (Ficoidaceae)*. Blandford Press, London.

**Jeffs, P.W., Allmann, G., Campbell, H.F., Farrier, D.S., Ganguli, G. and Hawks, R. L.** (1970) Alkaloids of *Sceletium* species. 111. The structures of four new alkaloids from *Sceletium strictum*. *Journal of Organic Chemistry* 35, 3512-3518.

**Jeffs, P.W., Archie, W.C., Hawks, R.L. and Farrier, D.S.** (1971) Biosynthesis of mesembrine and related alkaloids: the amino acid precursors. *Journal of the American Chemical Society* 93, 3752-3758.

**Jeffs, P.W., Capps, T., Johnson, D.B., Karle, J.M., Martin, N.H. and Rauckman, B.** (1974) Sceletiton alkaloids. VI. Minor alkaloids of *Sceletium namaquense* and *Sceletium strictum*. *Journal of Organic Chemistry* 39, 2703-2709.

**Jeffs, P.W., Karle, LM, and Martin, N.H.** (1978) Cinnamic acid intermediates as precursors to mesembrine and some observations on the late stages in the biosynthesis of the mesembrine alkaloids. *Phytochemistry* 17, 719-728.

**Juritz, C.F.** (1906) Kaffir beers, their nature and composition. *Cape Agricultural Journal*, 28, 35-47.

**Kellerman, T.S., Coetzer, LA.W. and Naude, T.W.** (1988) *Plant Poisonings and Mycotoxicoses of Livestock in Southern Africa*. Oxford University Press, Cape Town.

**Laidler, P.W.** (1928) The magic medicine of the Hottentots. *South African Journal of Science* 25, 433-447.

**Lewis, W.H. and Elvin-Lewis, P.F.** (1977) *Medicinal Botany: Plants Affecting Man's Health*. Wiley, New York.

**Libert, B. and Franceschi, V.R.** (1987) Oxalate in crop plants. *Journal of Agricultural and Food Chemistry* 35, 926-938.

**Marloth, R.** (1913) *The Flora of South Africa with Synoptical Tables of the Genera of Higher Plants. Vol. I*. William Wesley & Son, London.

**McKenna, D.J., Towers, G.H.N. and Abbott, F.** (1984) Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamines and -carboline constituents of ayahuasca. *Journal of Ethnopharmacology* 10, 195-223.

**Meiring, I.** (1898) Notes on some experiments with the active principle of *Mesembryanthemum tortuosum*. *Transactions of the South African Philosophical Society* 9, 48-50.

**Nienaber, G.S. and Raper, P.E.** (1977) *Toponymica Hottentolica. (Volume H-Z)*. HSRC, Pretoria.

**Popelak, A. and Lettenbauer, G.** (1968) The mesembrine alkaloids. In: R.H.F. Manske (Ed.), *The Alkaloids*. Vol.9. Academic Press, New York, pp. 467-482.

**Raper, P.E. and Boucher, M.** (Eds.) (1988) Robert Jacob Gordon. Cape Travels, 1777 to 1786. Vol. 1. The Brenthurst Press, Houghton, South Africa.

**Rimington, C. and Roets, G.C.S.** (1937) Notes upon the isolation of the alkaloidal constituent of the drug 'channa' or 'kougoed' (*Mesembryantheum anatomicum* and *Mesembryantheum tortuosum*). Onderstepoort Journal of Veterinary Science and Animal Industry 9, 187-191.

**Rood, B.** (1994) Uit die Veld-Aptek. Tafelberg, Cape Town.

**Rowley, G.D.** (1978) Caryophyllidae. In: V.E. Heywood (Ed.), Flowering Plants of the World. Oxford University Press, UK, pp. 63-67.

**Schapera, I.** (1963) The Khoisan Peoples of South Africa. Routledge, London.

**Schultes, R.E.** (1970) The botanical and chemical distribution of hallucinogens. Annual Review of Plant Physiology 21, 571-598.

**Schultes, R.E.** (1976). Indole Alkaloids in Plant Hallucinogens. *Planta Medica* 29, 330-342.

**Schultes, R.E.** (1977) The botanical and chemical distribution of hallucinogens, In: B.B. Du Toit (Ed.), Drugs, rituals and altered states of consciousness, A.A. Balkema, Rotterdam, pp. 25-55.

**Schultes, R.E. and Farnsworth, N.** (1980) Ethnomedical, botanical and phytochemical aspects of natural hallucinogens. Botanical Museum Leaflets of Harvard University 28, 123-214.

**Schultes, R.E. and Hofmann, A.** (1979) Plants of the Gods.. Origins of Hallucinogenic Use. Hutchinson, London.

**Smith, T.A.** (1977) Tryptamine and related compounds in plants. *Phytochemistry* 16, 171-175.

**Snyckers, F.O., Strelow, F., and Weichers, A.** (1971) The structures of partial racemic Sceletium alkaloid A4 and tortuosamine, pyridine alkaloids from *Sceletium tortuosum* N.E.Br. Chemical Communications (The Journal of the Chemical Society, Section D), 1467-1469.

**Stevens, R.V.** (1977) Alkaloid synthesis. In: J. ApSimon (Ed.), The Total Synthesis of Natural Products. Wiley, New York, pp. 439-554.

**Steyn, D.G.** (1934). The Toxicology of Plants in South Africa (Together With a Consideration of Poisonous Foodstuffs and Fungi). Central News Agency Ltd., London.

**Watt, J. M. and Breyer-Brandwijk, M.G.** (1932) The Medicinal and Poisonous Plants of Southern Africa. Livingstone, Edinburgh.

**Watt, J.M. and Breyer-Brandwijk, M.G.** (1962) The Medicinal and Poisonous Plants of Southern and Eastern Africa 2nd ed. Livingstone, London.

**Weil, A.T. and Davis, W.** (1994) *Bufo alvarius*: a potent hallucinogen of animal origin. *Journal of Ethnopharmacology* 41, 1-8.

**Weniger, B., Italiano, L., Beck, J-R, Bastida, J., Bergonon, S., Codina, C., Lobstein, A. and Anton, R.** (1995) Cytotoxic activity of Amaryllidaceae alkaloids. *Planta Medica* 61, 77-79.

**African Griffonia Seed** (contains 5-11% 5-HTP). 5-hydroxytryptophan, is the immediate precursor of serotonin. Low levels of serotonin are associated with sleep problems, depression, anxiety, compulsive disorders (including eating disorders), restless leg syndrome, migraines, fibromyalgia, and low pain threshold. Many people that are afflicted with one of those conditions often have others, which has led some researchers to label them collectively as "Low Serotonin Syndrome".

**Angst J, Woggon B, Schoepf J.** The treatment of depression with L-5-hydroxytryptophan versus imipramine. Results of two open and one double-blind study. *Arch Psychiatr Nervenkr.* 1977;224:175–186.

**Attele AS, Xie JT, Yuan CS.** Treatment of insomnia: an alternative approach. *Altern Med Rev.* 2000;5(3):249-259.

**Birdsall TC.** 5-Hydroxytryptophan: a clinically-effective serotonin precursor. *Altern Med Rev.* 1998;3:271–280.

**Bodner RA, Lynch T, Lewis L, Kahn D.** Serotonin syndrome. *Neurol.* 1995;45(2):219-223.

**Byerley WF, et al.** 5-Hydroxytryptophan: a review of its antidepressant efficacy and adverse effects. *J Clin Psychopharmacol.* 1987;7:127–137.

**Cangiano C, Ceci F, Cascino A, et al.** Eating behavior and adherence to dietary prescriptions in obese adult subjects treated with 5-hydroxytryptophan. *J Clin Nutr.* 1992;56:863–867.

**Caruso I, Sarzi Puttini P, Cazzola M, et al.** Double-blind study of 5-hydroxytryptophan versus placebo in the treatment of primary fibromyalgia syndrome. *J Int Med Res.* 1990;18:201–209.

**Cauffield JS, Forbes HJ.** Dietary supplements used in the treatment of depression, anxiety, and sleep disorders. *Lippincotts Prim Care Pract.* 1999; 3(3):290-304.

**Ceci F, Cangiano C, Cairella M, Cascino A, et al.** The effects of oral 5-hydroxytryptophan administration on feeding behavior in obese adult female subjects. *J Neural Transm.* 1989;76:109–117.

**DeBenedittis G, Massei R.** Serotonin precursors in chronic primary headache. A double-blind cross-over study with L-5-hydroxytryptophan vs. placebo. *J Neurosurg Sci.* 1985; 29:239–248.

**DeGiorgis G, et al.** Headache in association with sleep disorders in children: a psychodiagnostic evaluation and controlled clinical study—L-5-HTP versus placebo. *Drugs Exp Clin Res.* 1987;13:425–433.

**Dwuma-Badu D.** Constituents of West African medicinal plants. XVI. Griffonin and Griffonilide, novel constituents of *Griffonia simplicifolia*. *Lloydia.* 1976 Nov-Dec;39(6):385-90.

**Elko CJ, Burgess JL, Robertson WO.** Zolpidem-associated hallucinations and serotonin reuptake inhibition: a possible interaction. *J Toxicol Clin Toxicol.* 1998;36(3):195-203.

**Hines Burnham T, et al, eds.** *Drug Facts and Comparisons 2000.* 55th ed. St. Louis, MO: Facts and Comparisons; 2000.

**Juhl JH.** Primary fibromyalgia syndrome and 5-hydroxy-L-tryptophan: a 90-day open study. *Altern Med Rev.* 1998;3:367–375.

**Lescar J, Loris R, Mitchell E, Gautier C, Chazalet V, Cox V, Wyns L, Perez S, Breton C, Imberty A.** Isolectins I-A and I-B of *Griffonia (Bandeiraea) simplicifolia*. Crystal structure of metal-free GS I-B(4) and molecular basis for metal binding and monosaccharide specificity. *J Biol Chem.* 2002 Feb 22;277(8):6608-14. Epub 2001 Nov 19.

**Magnussen I, Nielson-Kudsk F.** Bioavailability and related pharmacokinetics in man of orally administered L-5-hydroxytryptophan in steady state. *Acta Pharmacol et Toxicol.* 1980;46:257–262.

**Martin TG.** Serotonin syndrome. *Ann Emerg Med.* 1996;28:520–526.

**Mason BJ, Blackburn KH.** Possible serotonin syndrome associated with tramadol and sertraline coadministration. *Ann Pharmacother.* 1997;31(2):175-177.

**Meyers S.** Use of neurotransmitter precursors for treatment of depression. *Altern Med Rev.* 2000;5(1):64-71.

**Murray MT, Pizzorno JE. Bromelain.** In: Pizzorno JE, Murray MT, eds. *Textbook of Natural Medicine.* Vol 1. 2nd ed. Edinburgh: Churchill Livingstone; 1999:783-794.

**Nicolodi M, Sicuteri F.** Fibromyalgia and migraine, two faces of the same mechanism. Serotonin as the common clue for pathogenesis and therapy. *Adv Exp Med Biol.* 1996;398:373–379.

**Nisijima K, Shimizu M, Abe T, Ishijuro T.** A case of serotonin syndrome induced by concomitant treatment with low-dose trazodone and amitriptyline and lithium. *Int Clin Psychopharmacol.* 1996;11(4):289-290.

**Puttini PS, Caruso I.** Primary fibromyalgia and 5-hydroxy-L-tryptophan: a 90-day open study. *J Int Med Res.* 1992;20:182–189.

**Reibring L, Agren H, Hartvig P, et al.** Uptake and utilization of [ $\beta$ - $^{11}$ C] 5-hydroxytryptophan (5-HTP) in human brain studied by positron emission tomography. *Psychiatry Research.* 1992;45:215–225.

**Shils ME, Olson JA, Shike M, eds.** *Modern Nutrition in Health and Disease.* 9th ed. Media, Pa: Williams & Wilkins; 1999.

**Tempel W, Tschampel S, Woods RJ.** The xenograft antigen bound to Griffonia simplicifolia lectin 1-B(4). X-ray crystal structure of the complex and molecular dynamics characterization of the binding site. *J Biol Chem.* 2002 Feb 22;277(8):6615-21. Epub 2001 Nov 19.

**Van Hiele LJ.** L-5-hydroxytryptophan in depression: the first substitution therapy in psychiatry? *Neuropsychobiology.* 1980; 6:230–240.

**Van Praag HM.** Management of depression with serotonin precursors. *Biol Psychiatry.* 1981;16:291–310.

**Zmilacher K, et al.** L-5-hydroxytryptophan alone and in combination with a peripheral decarboxylase inhibitor in the treatment of depression. *Neuropsychobiology.* 1988;20:28–33.

**Passionflower** was used in traditional remedies as a "calming" herb for anxiety, insomnia, seizures, and hysteria. During the early twentieth century, this herb was included in many over-the-counter sedatives and sleep aids. In Germany passionflower is available as an over-the-counter sedative (in combination with other calming herbs such as valerian and lemon balm). It is also used in German homeopathic medicine to treat pain, insomnia, and nervous restlessness. Today, professional herbalists use passionflower to help treat insomnia, tension, and other health problems related to anxiety and nervousness.

**Akhondzadeh S, Kashani L, Mobaseri M, Hosseini SH, Nikzad S, Khani M.** Passionflower in the treatment of opiates withdrawal: a double-blind randomized controlled trial. *J Clin Pharm Ther.* 2001 Oct;26(5):369-73.

**Akhondzadeh S, Naghavi HR, Vazirian M, Shayeganpour A, Rashidi H, Khani M.** Passionflower in the treatment of generalized anxiety: a pilot double-blind randomized controlled trial with oxazepam. *J Clin Pharm Ther.* 2001 Oct;26(5):363-7.

**Akhondzadeh S, Naghavi HR, Vazirian M, Shayeganpour A, Rashidi H, Khani M.** Passionflower in the treatment of generalized anxiety: a pilot double-blind randomized controlled trial with oxazepam. *J Clin Pharm Ther.* 2001;26(5):369-373.

**Akhondzadeh S.** Passionflower in the treatment of opiates withdrawal: a double-blind randomized controlled trial. *J Clin Pharm Ther.* 2001;26(5):369-373.

**Ansseau M.** Evaluation of activity parameters of passionflower dry extract capsules according to a "star" model. *J Pharm Belg.* 2004;59(4):97-9.

**Argento A, Tiraferri E, Marzaloni M.** Oral anticoagulants and medicinal plants. An emerging interaction. *Ann Ital Med Int.* 2000 Apr-Jun;15(2):139-43. Review.

**Baumgaertel A.** Alternative and controversial treatments for attention-deficit/hyperactivity disorder. *Pediatr Clin of North Am.* 1999;46(5):977-992.

**Bilia AR, Bergonzi MC, Mazzi G, Vincieri FF.** Analysis and stability of the constituents of artichoke and St. John's wort tinctures by HPLC-DAD and HPLC-MS. *Drug Dev Ind Pharm.* 2002 May;28(5):609-19.

**Bilia AR, Bergonzi MC, Gallori S, Mazzi G, Vincieri FF.** Stability of the constituents of Calendula, milk-thistle and passionflower tinctures by LC-DAD and LC-MS. *J Pharm Biomed Anal.* 2002 Oct 15;30(3):613-24.

**Block KI, Gyllenhaal C, Mead MN.** Safety and efficacy of herbal sedatives in cancer care. *Integr Cancer Ther.* 2004 Jun;3(2):128-48. Review.

**Blumenthal M, Busse WR, Goldberg A, et al. ed.** The Complete German Commission E Monographs. Boston, Mass: Integrative Medicine Communications; 1998: 179-180.

**Blumenthal M, Goldberg A, Brinckmann J.** Herbal Medicine: Expanded Commission E Monographs. Newton, MA: Integrative Medicine Communications; 2000:293-296.

**Bourin M, Bougerol T, Guitton B, Broutin E.** A combination of plant extracts in the treatment of outpatients with adjustment disorder with anxious mood: controlled study versus placebo. *Fundam Clin Pharmacol.* 1997;11:127-132.

**Brinker F.** Herb Contraindications and Drug Interactions. 2nd ed. Sandy, Ore: Eclectic Medical; 1998:109-110.

**Capasso A, Pinto A.** Experimental investigations of the synergistic-sedative effect of passiflora and kava. *Acta Therapeutica.* 1995;21:127-140

**Cauffield JS, Forbes HJ.** Dietary supplements used in the treatment of depression, anxiety, and sleep disorders. *Lippincotts Prim Care Pract.* 1999 May-Jun;3(3):290-304. Review.

**Cuzzolin L, Zaffani S, Benoni G.** Safety implications regarding use of phytomedicines. *Eur J Clin Pharmacol.* 2006 Jan;62(1):37-42. Epub 2005 Dec 3.

**Dhawan K.** Drug/substance reversal effects of a novel tri-substituted benzoflavone moiety (BZF) isolated from *Passiflora incarnata* Linn.--a brief perspective. *Addict Biol.* 2003 Dec;8(4):379-86.

**Dhawan K, Dhawan S, Sharma A.** *Passiflora*: a review update. *J Ethnopharmacol.* 2004 Sep;94(1):1-23.

**Dhawan K, Kumar S, Sharma A.** Nicotine reversal effects of the benzoflavone moiety from *Passiflora incarnata* Linneaus in mice. *Addict Biol.* 2002 Oct;7(4):435-41.

**Dhawan K, Kumar S, Sharma A.** Anxiolytic activity of aerial and underground parts of *Passiflora incarnata*. *Fitoterapia.* 2001 Dec;72(8):922-6.

**Dhawan K, Kumar S, Sharma A.** Antiasthmatic activity of the methanol extract of leaves of *Passiflora incarnata*. *Phytother Res.* 2003 Aug;17(7):821-2.

**Dhawan K, Sharma A.** Antitussive activity of the methanol extract of *Passiflora incarnata* leaves. *Fitoterapia.* 2002 Aug;73(5):397-9.

**De Souza KC, Petrovick PR, Bassani VL, Ortega GG.** The adjuvants aerosil 200 and Gelita-Sol-P influence on the technological characteristics of spray-dried powders from *Passiflora edulis* var. *flavicarpa*. *Drug Dev Ind Pharm.* 2000 Mar;26(3):331-6.

**Ernst E, ed.** *Passionflower. The Desktop Guide to Complementary and Alternative Medicine.* Edinburgh: Mosby; 2001:140-141.

**Ernst E.** Herbal remedies for anxiety - a systematic review of controlled clinical trials. *Phytomedicine.* 2006 Feb;13(3):205-8. Epub 2005 Aug 15.

**Fuchikami H, Satoh H, Tsujimoto M, Ohdo S, Ohtani H, Sawada Y.** Effects of herbal extracts on the function of human organic anion-transporting polypeptide OATP-B. *Drug Metab Dispos.* 2006 Apr;34(4):577-82. Epub 2006 Jan 13.

**Gomes CS, Campos AC, Torres OJ, Vasconcelos PR, Moreira AT, Tenorio SB, Tambara EM, Sakata K, Moraes Junior H, Ferrer AL.** *Passiflora edulis* extract and the healing of abdominal wall of rats: morphological and tensiometric study. *Acta Cir Bras.* 2006;21 Suppl 2:9-16.

**Gow PJ, Connelly NJ, Hill RL, Crowley P, Angus PW.** Fatal fulminant hepatic failure induced by a natural therapy containing kava. *Med J Aust.* 2003 May 5;178(9):442-3.

**Gruenwald J, Brendler T, Jaenicke C, ed.** *PDR for Herbal Medicines.* 2nd ed. Montvale, NJ: Medical Economics Company; 2000:573-575.

**Gyllenhaal C, Merritt SL, Peterson SD, Block KI, Gochenour T.** Efficacy and safety of herbal stimulants and sedatives in sleep disorders. *Sleep Med Rev.* 2000 Jun;4(3):229-251.

**Heck AM, DeWitt BA, Lukes AL.** Potential interactions between alternative therapies and warfarin. *Am J Health Syst Pharm.* 2000 Jul 1;57(13):1221-7; quiz 1228-30. Review.

**Kapadia GJ, Azuine MA, Tokuda H, Hang E, Mukainaka T, Nishino H, Sridhar R.** Inhibitory effect of herbal remedies on 12-O-tetradecanoylphorbol-13-acetate-promoted Epstein-Barr virus early antigen activation. *Pharmacol Res.* 2002 Mar;45(3):213-20.

**Krenn L.** Passion Flower (*Passiflora incarnata* L.)--a reliable herbal sedative. *Wien Med Wochenschr.* 2002;152(15-16):404-6. Review.

**Lans CA, Tambara EM, Tenorio SB, Torres OJ, Agulham MA, Araujo AC, Santis-Isolan PM, Oliveira RM, Arruda EC.** Ethnomedicines used in Trinidad and Tobago for urinary problems and diabetes mellitus. *J Ethnobiol Ethnomedicine.* 2006 Oct 13;2:45.

**Larzelere MM, Wiseman P.** Anxiety, depression, and insomnia. *Prim Care.* 2002 Jun;29(2):339-60, vii.

**Lutomski J, Segiet E, Szpunar K, Grisse K.** The importance of the passionflower in medicine. *Pharm Unserer Zeit.* 1981 Mar;10(2):45-9.

**Miyasaka LS, Atallah AN, Soares BG.** *Passiflora* for anxiety disorder. *Cochrane Database Syst Rev.* 2007 Jan 24;(1):CD00451

**Montanher AB, Zucolotto SM, Schenkel EP, Frode TS.** Evidence of anti-inflammatory effects of *Passiflora edulis* in an inflammation model. *J Ethnopharmacol.* 2007 Jan 19;109(2):281-8. Epub 2006 Jul 31.

**Mourvaki E, Gizzi S, Rossi R, Rufini S.** Passionflower fruit-a "new" source of lycopene? *J Med Food.* 2005 Spring;8(1):104-6.

**Newall C, Anderson L, Phillipson J.** *Herbal Medicines: A Guide for Health-care Professionals.* London, England: Pharmaceutical Press; 1996: 206-207.

**Rotblatt M, Ziment I.** *Evidence-Based Herbal Medicine.* Philadelphia, PA: Hanley & Belfus, Inc; 2002;294-297.  
**Rowe CA, Nantz MP, Deniera C, Green K, Talcott ST, Percival SS.** Inhibition of neoplastic transformation of benzo[alpha]pyrene-treated BALB/c 3T3 murine cells by a phytochemical extract of passionfruit juice. *J Med Food.* 2004 Winter;7(4):402-7.

**Rudnicki M, Silveira MM, Pereira TV, Oliveira MR, Reginatto FH, Dal-Pizzol F, Moreira JC.** Protective effects of *Passiflora alata* extract pretreatment on carbon tetrachloride induced oxidative damage in rats. *Food Chem Toxicol.* 2007 Apr;45(4):656-61. Epub 2006 Nov 2.

**Solbakken AM, Rorbakken G, Gundersen T.** Nature medicine as intoxicant. *Tidsskr Nor Laegeforen.* 1997 Mar 20;117(8):1140-1.

**Soulimani R, Younos C, Jarmouni S, Bousta D, Misslin R, Mortier F.** Behavioural effects of *Passiflora incarnata* L. and its indole alkaloid and flavonoid derivatives and maltol in the mouse. *J Ethnopharmacol.* 1997;57(1):11-20.

**Speroni E, Minghetti A.** Neuropharmacological activity of extracts from *Passiflora incarnata*. *Planta Medica.* 1988;54:488-491.

**Spinella M.** Herbal Medicines and Epilepsy: The Potential for Benefit and Adverse Effects. *Epilepsy Behav.* 2001 Dec;2(6):524-532.

**Vargas AJ, Geremias DS, Provensi G, Fornari PE, Reginatto FH, Gosmann G, Schenkel EP, Frode TS.** *Passiflora alata* and *Passiflora edulis* spray-dried aqueous extracts inhibit inflammation in mouse model of pleurisy. *Fitoterapia.* 2007 Feb;78(2):112-9. Epub 2006 Nov 14.

**Wheatley D.** Medicinal plants for insomnia: a review of their pharmacology, efficacy and tolerability. *J Psychopharmacol.* 2005 Jul;19(4):414-21.

**White L, Mavor S.** Kids, Herbs, Health. Loveland, Colo: Interweave Press; 1998:22, 38.

**Zal HM.** Five herbs for depression, anxiety, and sleep disorders. Uses, benefits, and adverse effects. Consultant. 1999;3343-3349.

**Colloidal Silver** has been found to have antibacterial properties. Research and published studies have shown colloidal silver prevents damage by free radicals, especially the hydroxide free radicals. Colloidal silver has been used in management of burns, and is one constituent of an experimental wound dressing for infection control and tissue healing potential. It has been used to cleanse the body of heavy metals.

**Brentano L, Margraf H, Monafó WW, Moyer CA.** Antibacterial efficacy of a colloidal silver complex. Surg Forum. 1966;17:76-8

**Huang SK, Martin FJ, Jay G, Vogel J, Papahadjopoulos D, Friend DS.** Extravasation and transcytosis of liposomes in Kaposi's sarcoma-like dermal lesions of transgenic mice bearing the HIV tat gene. Am J Pathol. 1993 Jul;143(1):10-4.

**Kim DW, Hong GH, Lee HH, Choi SH, Chun BG, Won CK, Hwang IK, Won MH.** Effect of colloidal silver against the cytotoxicity of hydrogen peroxide and naphthazarin on primary cultured cortical astrocytes. Int J Neurosci. 2007 Mar;117(3):387-400.

**Lansdown AB.** Controversies over colloidal silver. J Wound Care. 2003 Mar;12(3):120.

**Lansdown AB.** Silver in health care: antimicrobial effects and safety in use. Curr Probl Dermatol. 2006;33:17-34.

**Monafó WW.** The management of burns. II. The silver nitrate method. Curr Probl Surg. 1969 Feb;:53-66.

**Morris PJ, Bondoc CC, Burke JF.** The control of burn wound sepsis with 0.5 per cent silver nitrate. Aust N Z J Surg. 1968 Nov;38(2):108-11.

**Serra N, Torres OG, Romo MI, Llovera JM, Vigil-Escalera LJ, Soto MA, Gonzalez-Parra S.** Hydro-colloidal dressings which release hydro-active silver. Rev Enferm. 2005 Feb;28(2):13-8.

**Ozone** when incorporated as an ozonoid in a gel or cream, has important anti-microbial properties. The products are anti-bacterial, anti-fungal, and anti-viral. They impart additional oxygen to cellular structures, and increase the potential for cellular regeneration and repair. They are important in infection control and wound management.

**Bocci V.** Does ozone therapy normalize the cellular redox balance? Implications for therapy of human immunodeficiency virus infection and several other diseases. Med Hypotheses 1996; 46: 150-154.

**Bocci V.** Ozone as a bioregulator. Pharmacology and toxicology of ozone therapy today. J Biol Regul Homeost Agents 1996; 10: 31-53

**Bocci V.** Biological and clinical effects of ozone. Has ozone therapy a future in medicine? Br J Biomed Sci 1999; 56: 270-279.

**Bocci V.** Ozone as Janus: This controversial gas can be either toxic or medically useful. Mediators of Inflammation. 13(1): 3-11, 2004

**Bocci V, Aldinucci C.** Rational bases for using oxygen-ozonotherapy as a biological response modifier in sickle cell anemia and beta-thalassemia: a therapeutic perspective. *J Biol Regul Homeost Agents*. 2004, 18:38-44.

**Bocci V, Luzzi E, Corradeschi F.** Studies on the biological effects of ozone: 4. Cytokine production and glutathione levels in human erythrocytes. *J Biol Regul Homeost Agents* 1993; 7: 133-138.

**Carpendale MT, Freeberg JK.** Does ozone alleviate AIDS diarrhea? *J Clin Gastroenterol* 17(2):142-145, 1993.

**Carpendale MT, Freeberg JK.** Ozone inactivates extracellular human immunodeficiency virus at non-toxic concentrations. Fourth Intl Conf AIDS, Stockholm, abstract 3560, 1988.

**Carpendale MT, Freeberg JK.** Ozone inactivates HIV at noncytotoxic concentrations. *Antiviral Res*. 1991 Oct;16(3):281-92.

**Castañeira ET, Cruz O, Menéndez S1.** Dyschroma Treated With 'OLEOZON'. Abstract, 1995 International Ozone Conference, Havana, Cuba. Elpidio Berovides Educational Polyclinic Center, Cuba. 1 Ozone Research Center, Cuba. Chang H, Fulton, Lynch E Antimicrobial Efficacy of Ozone on Enterococcus faecalis. IADR Abstract 2003

**Chahverdiani B, Thadj-Bakhche A.** Ozone treatment in root canal therapy. Introduction and general discussion *Acta Med Iran*. 1976;19(3):192-200.

**de Gruijl FR.** Skin cancer and solar UV radiation. *Eur J Cancer*. 1999 Dec;35(14):2003-9.

**Domingo H, Abu-Naba L, Al Shorman H, Holmes J, Marashdeh M, Abu-Salem O, Smith C, Freeman R, and Lynch E.** Reducing barriers to care in patients managed with ozone. *J. Dent. Res*, 2003. 82A: p. 0677

**Ed McCabe,** in <http://www.silvermedicine.org/ed-mccabe-ozone.html>

**Fitzpatrick TB.** The skin cancer cascade: from ozone depletion to melanoma--some definitions and some new interpretation, 1996. *J Dermatol*. 1996 Nov;23(11):816-20.

**Freeman BA, Sharman MC, Mudd JB.** Reaction of ozone with phospholipid vesicles and human erythrocyte ghosts. *Arch Biochem Biophys*. 1979 Oct 1;197(1):264-72.

**Friedman LI, Stromberg RR.** Viral inactivation and reduction in cellular blood products. *Rev Fr Transfus Hemobiol*. 1993 Jan;36(1):83-91. Review

**Garber GE, Cameron DW, Hawley-Foss N, Greenway D, Shannon ME.** The use of ozone-treated blood in the therapy of HIV infection and immune disease: a pilot study of safety and efficacy. *AIDS*. 1991 Aug;5(8):981-4.

**Goldstein BD, Balchum OJ.** Effect of ozone on lipid peroxidation in the red blood cell. *Proc Soc Exp Biol Med*. 1967 Nov;126(2):356-8.

**Goldstein BD, Lodi C, Collinson C, Balchum OJ.** Ozone and lipid peroxidation. *Arch Environ Health*. 1969 Apr;18(4):631-5.

**Gutteridge JM, Halliwell B.** Iron toxicity and oxygen radicals. *Baillieres Clin Haematol*. 1989 Apr;2(2):195-256.

**Holmes J.** New technologies in dental care. *Dentistry*, 2002. 16th May: p. 14. 3-part series

**Holmes J and Daley T.** Sensitivity and cracked teeth; treatment with ozone. *Dental Practice* 2003; June

**Holmes J, Grootveld M, Smith C, Claxson A, and Lynch E.** Bleaching of Components Responsible for Extrinsic Tooth Discoloration by Ozone. *J Dent Res* 82(Spec Iss A):0615, 2003

**Hooker MH, Gazzard BG.** Ozone-treated blood in the treatment of HIV infection. *AIDS*. 1992 Jan;6(1):131.

**Lynch E, Grootveld M, Holmes J, Silwood CJ, Claxson AWD, Prinz J, Toms H.** 1H NMR Analysis of Ozone-treated Grapeseed, Olive and Sunflower Oils. *AADR Abstract no.* 182; 2003

**Jordan L, Beaver K, Foy S.** Ozone treatment for radiotherapy skin reactions: is there an evidence base for practice? *Eur J Oncol Nurs*. 2002 Dec;6(4):220-7.

**Lipatov KV, Sopromadze MA, Shekhter AB, Rudenko TG, Emel'ianov AIu.** Ozone-ultrasonic therapy in the treatment of purulent wounds. *Khirurgiia (Mosk)*. 2002;(1):36-9.

**Moseley R, Waddington RJ, Embery G.** Degradation of glycosaminoglycans by reactive oxygen species derived from stimulated polymorphonuclear leukocytes. *Biochim Biophys Acta*. 1997 Dec 31;1362(2-3):221-31.

**Ovchinnikov IuM, Sin'kov EV.** Use of gaseous ozone and ozonized solutions in the treatment of chronic suppurative otitis media. *Vestn Otorinolaringol*. 1998;(6):11-2.

**Pogosov VS, Miroshnichenko NA, Tafintsev AN.** Medical ozone in combination with low-frequency ultrasound therapy in the treatment of patients with chronic purulent otitis media. *Vestn Otorinolaringol*. 2001;(5):24-5.

**Pryor WA, Stanley JP, Blair E.** Autoxidation of polyunsaturated fatty acids: II. A suggested mechanism for the formation of TBA-reactive materials from prostaglandin-like endoperoxides. *Lipids*. 1976 May;11(5):370-9.

**Sechi L.A, Lezcano I, Nunez N, Espim M, Duprè I, Pinna A, Molicotti P, Fadda G & Zanetti S.** Antibacterial activity of ozonized sunflower oil (Oleozon). *Journal of Applied Microbiology*, Volume 90 Issue 2 Page 279 - February 2001

**Slaper H, Velders GJ, Daniel JS, de Gruijl FR, van der Leun JC.** Estimates of ozone depletion and skin cancer incidence to examine the Vienna Convention achievements. *Nature*. 1996 Nov 21;384(6606):256-8.

**Thiele JJ, Schroeter C, Hsieh SN, Podda M, Packer L.** The antioxidant network of the stratum corneum. *Curr Probl Dermatol*. 2001;29:26-42.

**Urbach F.** Ultraviolet radiation and skin cancer of humans. *J Photochem Photobiol B*. 1997 Aug;40(1):3-7.

**Waddington RJ, Moseley R, Embery G.** Reactive oxygen species: a potential role in the pathogenesis of periodontal diseases. *Oral Dis*. 2000 May;6(3):138-51.

**Wells KH, Latino J, Gavalchin J, Poiesz BJ.** Inactivation of human immunodeficiency virus type 1 by ozone in vitro. *Blood*. 1991 Oct 1;78(7):1882-90.

**Potassium Sorbate** has shown antifungal and antimicrobial activity. It is used for its anti-microbial properties in infection control and wound management. It is used extensively in the food industry and as a supplement.

**Venturini ME, Blanco D, Oria R.** In vitro antifungal activity of several antimicrobial compounds against *Penicillium expansum*. *J Food Prot*. 2002 May;65(5):834-9

**Luck E.** Food applications of sorbic acid and its salts. *Food Addit Contam*. 1990 Sep-Oct;7(5):711-5.